Skip to main content

Table 4 Late-sequelae hazard ratios for different risk factors

From: Late somatic sequelae after treatment of childhood cancer in Slovenia

Risk factor HR CI P
Gender: Female (reference group) 1.00   
Male 0.85 0.71–1.00    0.06
Age: from 0 to 5 years (reference group) 1.00   
From 5 to 10 years 0.65 0.51–0.84 <0.01
From 10 to 16 years 0.40 0.31–0.52 <0.01
Diagnosis period: 1957-1975 (reference group) 1.00   
1976-1980 1.15 0.83–1.59    0.41
1981-1985 1.22 0.89–1.68    0.21
1986-1990 1.02 0.74–1.41    0.89
1991-1995 0.90 0.63–1.28    0.56
1996-2005 1.14 0.81–1.61    0.45
Treatment: Surgery only (S, reference group) 1.00   
Radiotherapy only (RT) 1.91 1.06–3.47    0.03
Chemotherapy only (CHT) 0.96 0.53–1.74    0.88
Surgery and Radiotherapy (S_RT) 3.25 2.31–4.57 <0.01
Surgery and Chemotherapy (S_CHT) 2.49 1.76–3.54 <0.01
Radio and Chemotherapy (RT_CHT) 2.29 1.54–3.40 <0.01
Surgery, Radio and Chemotherapy (S_RT_CHT) 3.80 2.71–5.32 <0.01
Primary diagnosis: Leukemia (reference group) 1.00   
NHL 1.82 1.21–2.74 <0.01
Neuroblastoma 2.27 1.23–4.20    0.01
Other malignant neoplasms 2.93 1.69–5.06 <0.01
Rhabdomyosarcoma 2.97 1.79–4.93 <0.01
HD 3.09 2.14–4.45 <0.01
CNS 3.60 2.33–5.55 <0.01
Soft-tissue sarcomas 4.00 2.51–6.38 <0.01
Malignant bone tumors 4.54 2.81–7.31 <0.01
Other carcinomas 4.62 2.73–7.84 <0.01
Renal tumors 6.02 3.71–9.76 <0.01
  1. Cox regression estimates of the late sequelae hazard ratios (HR) by gender, age at diagnosis, diagnosis period, therapy, and primary diagnosis, 95% confidence intervals (CI) thereof, and the p-values for the test of the significant difference from the indicated reference groups.